Differential methylation of TMEM232 and ZBTB16 was observed in MS patients and then replicated in an independent sample. IFN-beta therapy induces hypomethylation of RSAD2, MX1, and PLSCR1. This evidence concerns the gene TMEM232 and myeloid sarcoma.